DISCLOSURES: The authors reported no conflicts of interest.
Version of Record online: 17 JUN 2010
Copyright © 2010 American Cancer Society, Inc.
CA: A Cancer Journal for Clinicians
Volume 60, Issue 4, pages 222–243, July/August 2010
How to Cite
Cook, K. M. and Figg, W. D. (2010), Angiogenesis Inhibitors: Current Strategies and Future Prospects. CA: A Cancer Journal for Clinicians, 60: 222–243. doi: 10.3322/caac.20075
- Issue online: 7 JUL 2010
- Version of Record online: 17 JUN 2010
Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (eg, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor), receptor tyrosine kinases, and transcription factors such as hypoxia inducible factor, as well as molecules involved in mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of antitumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.